Cutaneous adverse events following treatment with third-generation EGFR tyrosine kinase inhibitors

被引：0
|
作者：
Li Pomi, Federica [1 ]
Vaccaro, Federico [2 ]
Borgia, Francesco [1 ]
Irrera, Natasha [1 ]
Vaccaro, Mario [1 ]
机构：
[1] Univ Messina, Dept Clin & Expt Med, Sect Dermatol, I-98125 Messina, Italy
[2] Univ Modena & Reggio Emilia, Dept Dermatol, Modena, Italy
来源：
ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY | 2024年 / 159卷 / 02期
关键词：
D O I：
10.23736/S2784-8671.23.07781-2
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：212 / 214
页数：3
相关论文
共 50 条
  • [41] Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
    Ortiz-Cuaran, Sandra
    Scheffler, Matthias
    Plenker, Dennis
    Dahmen, Ilona
    Scheel, Andreas H.
    Fernandez-Cuesta, Lynnette
    Meder, Lydia
    Lovly, Christine M.
    Persigehl, Thorsten
    Merkelbach-Bruse, Sabine
    Bos, Marc
    Michels, Sebastian
    Fischer, Rieke
    Albus, Kerstin
    Koenig, Katharina
    Schildhaus, Hans-Ulrich
    Fassunke, Jana
    Ihle, Michaela A.
    PasternackO, Helen
    Heydt, Carina
    Becker, Christian
    Altmueller, Janine
    Ji, Hongbin
    Mueller, Christian
    Florin, Alexandra
    Heuckmann, Johannes M.
    Nuernberg, Peter
    Ansen, Sascha
    Heukamp, Lukas C.
    Berg, Johannes
    Pao, William
    Peifer, Martin
    Buettner, Reinhard
    Wolfe, Juergen
    Thomas, Roman K.
    Sos, Martin L.
    CLINICAL CANCER RESEARCH, 2016, 22 (19) : 4837 - 4847
  • [42] Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
    Wright, Natalie M. Andrews
    Goss, Glenwood D.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S247 - S264
  • [43] Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
    Du, Xiaojing
    Yang, Biwei
    An, Quanlin
    Assaraf, Yehuda G.
    Cao, Xin
    Xia, Jinglin
    INNOVATION, 2021, 2 (02):
  • [44] Associations of early adverse events with clinical outcomes in patients with NSCLC treated with EGFR tyrosine kinase inhibitors
    Lin, Fang-Ju
    Lin, Wen-Yen
    Wang, Chi-Chuan
    Shih, Jin-Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer
    Lee, Jiyun
    Kim, Hong Sook
    Lee, Boram
    Kim, Hee Kyung
    Sun, Jong-Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    Lee, Se-Hoon
    CANCER, 2020, 126 (11) : 2704 - 2712
  • [46] Third-generation inhibitors of mTOR
    Shokat, Kevan M.
    CANCER RESEARCH, 2017, 77
  • [47] Structural Differences between Wild-Type and Double Mutant EGFR Modulated by Third-Generation Kinase Inhibitors
    Lowder, Melissa A.
    Doerner, Amy E.
    Schepartz, Alanna
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2015, 137 (20) : 6456 - 6459
  • [48] A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
    Gawli, Chandrakant S.
    Patil, Chandragouda R.
    Patel, Harun M.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2025, 123
  • [49] Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
    Jabbour, E.
    Deininger, M.
    Hochhaus, A.
    LEUKEMIA, 2011, 25 (02) : 201 - 210
  • [50] Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
    E Jabbour
    M Deininger
    A Hochhaus
    Leukemia, 2011, 25 : 201 - 210
12345